Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia

Leukemia

Volumn 24, Issue 1, 2010, Pages 237-239

  Shustik, C ^a,b   Turner, A R ^c   Desjardins, P ^d   Fernandez, L ^e   Rubin, S ^f   Larratt, L ^g   Duncan, A M V ^b   Rizi, D ^b   Sadura, A ^a   Shepherd, L ^a   Li, D ^a   Rassenti, L ^h   Kipps, T ^h  

^a Queen's Cancer Research Institute   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d HÔPITAL CHARLES LEMOYNE   (Canada)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^f MONCTON HOSPITAL   (Canada)

^g UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FLUDARABINE; HEMOPOIETIC GROWTH FACTOR; PROTEIN KINASE ZAP 70;

BONE MARROW SUPPRESSION; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE SEQUENCE; HUMAN; INFECTION; LETTER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 74249094451     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.205     Document Type: Letter

References (8)

1. Foran JM, Oscier D, Orchard J, Johnson SA, Tighe M, Cullen MH et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with 'low-grade' non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 1999; 17: 1574-1579.
2. Rossi JF, van HA, de BK, Johnson SA, Bron D, Foussard C et al. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2004; 22: 1260-1267.
3. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
4. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916. (Pubitemid 32064784)
5. Dewald GW, Brockman SR, Paternoster SF, Bone ND, O'Fallon JR, Allmer C et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003; 121: 287-295.
6. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893-901.
7. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al., the German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
8. Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares R et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239.